(AOF) – Poxel announces that as of September 30, 2023, its cash and cash equivalents amounted to 5.3 million euros. The biotech specialist in innovative treatments against metabolic diseases, including non-alcoholic steatohepatitis (NASH), specifies that by including the entire drawdown of the equity financing line set up with Iris, its financing horizon runs until ‘at the end of the 2nd quarter of 2025. Poxel achieved a turnover of 1.61 million euros for the nine months ended September 30, compared to 286,000 euros a year earlier.
“We continue our active discussions with investors and potential partners, and are mobilized to obtain additional financing to advance our rare disease strategy and launch Phase II proof of concept (POC) studies in the ALD,” said Thomas Kuhn, Managing Director of Poxel.
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
